Broyhill Asset Management Invests $306,000 in Becton, Dickinson and Company (NYSE:BDX)

Broyhill Asset Management bought a new position in Becton, Dickinson and Company (NYSE:BDX - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 1,348 shares of the medical instruments supplier's stock, valued at approximately $306,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. CreativeOne Wealth LLC increased its stake in shares of Becton, Dickinson and Company by 20.4% in the 4th quarter. CreativeOne Wealth LLC now owns 2,630 shares of the medical instruments supplier's stock worth $597,000 after purchasing an additional 445 shares in the last quarter. Mariner LLC lifted its position in shares of Becton, Dickinson and Company by 6.4% during the 4th quarter. Mariner LLC now owns 43,331 shares of the medical instruments supplier's stock valued at $9,830,000 after buying an additional 2,615 shares in the last quarter. Cohen & Steers Inc. grew its stake in shares of Becton, Dickinson and Company by 5.4% during the 4th quarter. Cohen & Steers Inc. now owns 1,142 shares of the medical instruments supplier's stock valued at $259,000 after acquiring an additional 58 shares during the period. SageView Advisory Group LLC purchased a new stake in Becton, Dickinson and Company in the 4th quarter worth approximately $516,000. Finally, Savvy Advisors Inc. bought a new stake in Becton, Dickinson and Company during the 4th quarter worth approximately $252,000. Hedge funds and other institutional investors own 86.97% of the company's stock.

Becton, Dickinson and Company Trading Down 1.0 %

Shares of NYSE:BDX traded down $1.91 during trading on Friday, reaching $198.50. The company's stock had a trading volume of 4,062,543 shares, compared to its average volume of 1,710,218. Becton, Dickinson and Company has a 12 month low of $193.03 and a 12 month high of $251.99. The company has a current ratio of 1.13, a quick ratio of 0.63 and a debt-to-equity ratio of 0.69. The firm's 50 day simple moving average is $220.84 and its two-hundred day simple moving average is $228.58. The stock has a market capitalization of $56.99 billion, a PE ratio of 32.97, a price-to-earnings-growth ratio of 1.63 and a beta of 0.35.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its quarterly earnings data on Wednesday, February 5th. The medical instruments supplier reported $3.43 EPS for the quarter, topping the consensus estimate of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. On average, research analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, March 31st. Investors of record on Monday, March 10th were issued a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a yield of 2.10%. The ex-dividend date was Monday, March 10th. Becton, Dickinson and Company's payout ratio is currently 69.10%.

Becton, Dickinson and Company declared that its Board of Directors has approved a share repurchase program on Tuesday, January 28th that allows the company to repurchase 10,000,000 shares. This repurchase authorization allows the medical instruments supplier to reacquire shares of its stock through open market purchases. Shares repurchase programs are typically a sign that the company's leadership believes its stock is undervalued.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on BDX shares. Piper Sandler increased their price target on Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an "overweight" rating in a research note on Tuesday, January 28th. Barclays reduced their price target on shares of Becton, Dickinson and Company from $279.00 to $261.00 and set an "overweight" rating on the stock in a report on Monday, April 7th. Finally, StockNews.com upgraded Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research report on Wednesday, April 2nd. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus price target of $275.71.

Insiders Place Their Bets

In other news, EVP David Shan sold 500 shares of the stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $240.00, for a total transaction of $120,000.00. Following the transaction, the executive vice president now owns 5,741 shares of the company's stock, valued at approximately $1,377,840. This represents a 8.01 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Michael David Garrison sold 479 shares of the company's stock in a transaction dated Wednesday, April 9th. The stock was sold at an average price of $197.28, for a total transaction of $94,497.12. Following the completion of the sale, the executive vice president now directly owns 4,887 shares of the company's stock, valued at approximately $964,107.36. This trade represents a 8.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 4,078 shares of company stock worth $915,986 over the last quarter. Company insiders own 0.36% of the company's stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.